<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838030</url>
  </required_header>
  <id_info>
    <org_study_id>ECAALA</org_study_id>
    <nct_id>NCT02838030</nct_id>
  </id_info>
  <brief_title>Efficacy of Aspirin and L-arginine in High Risk Preeclamptic</brief_title>
  <official_title>Efficacy of the Combination of Acetylsalicylic Acid and L-arginine to Prevent Preeclampsia in Pregnant High Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PhD Ernesto Javier Ramírez Lizardo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PhD Sylvia Elena Totsuka Sutto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PhD Fernando Grover Páez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MD Diego Hernández Molina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, the incidence of preeclampsia ranges from 2 to 10% of pregnancies. The World&#xD;
      Health Organization (WHO) estimates that the incidence of preeclampsia is seven times higher&#xD;
      in developing countries than in developed (2.8% and 0.4%). In Mexico it is estimated that&#xD;
      preeclampsia - eclampsia is a major cause of maternal and perinatal morbidity and mortality.&#xD;
      Because it is an idiopathic heterogeneous syndrome associated with endothelial damage, so far&#xD;
      there is no effective treatment to decrease the morbidity and mortality of this entity, so it&#xD;
      is necessary to strengthen prevention; the use of aspirin alone is inconclusive, in addition&#xD;
      to the information the investigators have reduced the effect of these strategies on arterial&#xD;
      stiffness; Moreover, it has been observed that L-arginine lowers blood pressure in this&#xD;
      population. It is for this that is of interest to know the efficacy and safety of the&#xD;
      combination of L-arginine low dose, which is known as an important eNOS in NO production&#xD;
      substrate, and aspirin for its qualities of antiinflammatory and anticoagulant in the&#xD;
      prevention of preeclampsia and also determine their effect on arterial stiffness as a&#xD;
      noninvasive method, as is the applanation tonometry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will conduct a clinical trial, double-blind, randomized and placebo control group female&#xD;
      patients with 12 weeks of gestation have one or more risk factors for developing&#xD;
      preeclampsia. 2 groups will be formed with 82 patients each, chance will determine the&#xD;
      intervention (acetylsalicylic + L-arginine acetylsalicylic acid or acid + placebo). At the&#xD;
      beginning and end of the intervention clinical and laboratory determinations, the end will be&#xD;
      determined in both groups the incidence of preeclampsia, severity and number needed to treat&#xD;
      is made. The data obtained were analyzed using SPSS statistical software version 22. It was&#xD;
      considered statistically significant at p &lt;0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of preeclampsia</measure>
    <time_frame>from 20 weeks gestation until 37 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>severity of preeclampsia</measure>
    <time_frame>from 20 weeks gestation until 37 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary edema maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress syndrome maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulopathy maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal damage maternal</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal mortality</measure>
    <time_frame>at week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth restriction</measure>
    <time_frame>birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal mortality</measure>
    <time_frame>birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood pressure maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects maternal</measure>
    <time_frame>from 12 weeks gestation until 37 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>High Risk Pregnancy</condition>
  <arm_group>
    <arm_group_label>acetylsalicylic acid and L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acetylsalicylic acid and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>3 gr per day</description>
    <arm_group_label>acetylsalicylic acid and L-arginine</arm_group_label>
    <other_name>arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for L-arginine)</intervention_name>
    <description>3 gr per day</description>
    <arm_group_label>acetylsalicylic acid and placebo</arm_group_label>
    <other_name>Magnesia calcined</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>3 gr per day</description>
    <arm_group_label>acetylsalicylic acid and L-arginine</arm_group_label>
    <arm_group_label>acetylsalicylic acid and placebo</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant before 12 weeks of gestation&#xD;
&#xD;
          -  High risk of preeclampsia&#xD;
&#xD;
          -  Signature of informed consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Noncompliance &gt; 20% of drug intake&#xD;
&#xD;
          -  Lack of tolerability L-arginine or acetylsalicylic acid&#xD;
&#xD;
          -  Compliance with at least one non-inclusion criteria during the course of the study&#xD;
&#xD;
          -  Serious adverse event&#xD;
&#xD;
          -  Withdrawal of consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonel García Benavides, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antiguo Hospital Civil Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Leonel Garcia Benavides</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>L-arginine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

